Usually biotech start-up stock valuation is built as the IP progress, IMU is doing the complete opposite in the last 18 months, possibly @johndprent was right and CVI sold it down to 2c so this recent drop isn't based on the fundamental. Like management said, they don't know why the MC has dropped so much despite no negative clinical trial updates, maybe they think the extremely high O/S play a part in this and also PH's shares loan to Macquire.......
IMU Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)